BCACP Gastrointestinal Disorders Management — Questions and Answers
Question 1: A patient is diagnosed with Helicobacter pylori-associated peptic ulcer disease. He has no penicillin allergy and has not previously received clarithromycin. Which regimen is considered first-line eradication therapy in areas with known clarithromycin resistance rates below 15%?
- Bismuth quadruple therapy: bismuth + metronidazole + tetracycline + PPI for 14 days
- Clarithromycin triple therapy: PPI + clarithromycin + amoxicillin for 14 days (Correct answer)
- Sequential therapy: PPI + amoxicillin for 5 days then PPI + clarithromycin + metronidazole for 5 days
- Dual therapy: PPI + amoxicillin for 7 days
Correct answer: Clarithromycin triple therapy: PPI + clarithromycin + amoxicillin for 14 days
Clarithromycin-based triple therapy (PPI + clarithromycin + amoxicillin) for 14 days remains first-line in regions where clarithromycin resistance is less than 15% and the patient has no prior macrolide exposure. The ACG 2017 guidelines support this regimen in those circumstances. Bismuth quadruple therapy is preferred in areas of high clarithromycin resistance or in patients with prior macrolide exposure. Sequential therapy is an alternative with similar efficacy.
Question 2: A patient with gastroesophageal reflux disease (GERD) has had an inadequate response to lifestyle modifications. According to a step-up approach, which therapy should be tried FIRST before escalating to a proton pump inhibitor (PPI)?
- H2 receptor antagonist (H2RA) taken as needed or regularly (Correct answer)
- Sucralfate four times daily
- Prokinetic agent such as metoclopramide
- Antacid therapy alone is no longer recommended in any GERD patient
Correct answer: H2 receptor antagonist (H2RA) taken as needed or regularly
The step-up approach to GERD management begins with lifestyle modifications, then antacids or H2 receptor antagonists (H2RAs) for mild or intermittent symptoms before advancing to PPIs for moderate-to-severe or frequent symptoms. H2RAs (e.g., famotidine) are appropriate as a step between antacids and PPIs. Sucralfate is used primarily for peptic ulcer disease, not GERD. Metoclopramide has a limited and cautious role due to neurological adverse effects.
Question 3: A patient with Crohn's disease involving the ileum is in remission on azathioprine monotherapy. Which biologic agent would be most appropriate to ADD for a patient with moderate-to-severe disease who fails to maintain remission on an immunomodulator alone?
- Vedolizumab (anti-integrin)
- Infliximab (anti-TNF-alpha) (Correct answer)
- Ustekinumab (anti-IL-12/23)
- All three options are equally preferred as initial biologic therapy per ACG guidelines
Correct answer: Infliximab (anti-TNF-alpha)
Anti-TNF agents (infliximab, adalimumab) are the most established and guideline-preferred first-line biologic therapy for moderate-to-severe Crohn's disease, often combined with an immunomodulator (combo therapy reduces immunogenicity). Vedolizumab and ustekinumab are effective alternatives, particularly for patients who fail or cannot tolerate anti-TNF agents, but infliximab has the most robust long-term efficacy and safety data as an initial biologic in Crohn's disease.
Question 4: A patient taking a PPI for long-term GERD management asks about potential risks associated with chronic PPI use. Which of the following is the MOST well-established adverse effect of long-term PPI therapy?
- Hepatocellular carcinoma
- Hypomagnesemia (Correct answer)
- Pulmonary fibrosis
- Type 2 diabetes mellitus
Correct answer: Hypomagnesemia
Hypomagnesemia is a well-established and FDA-labeling-recognized adverse effect of long-term PPI use, particularly after more than one year of therapy. PPIs impair intestinal magnesium absorption. Other recognized long-term risks include increased risk of C. difficile infection, community-acquired pneumonia, vitamin B12 deficiency, and bone fractures. Hepatocellular carcinoma and pulmonary fibrosis are not established PPI adverse effects. Type 2 diabetes association is observational with unclear causality.
Question 5: A 35-year-old patient with irritable bowel syndrome with predominant constipation (IBS-C) has failed dietary fiber supplementation and osmotic laxatives. Which FDA-approved pharmacological agent is indicated specifically for IBS-C?
- Alosetron
- Rifaximin
- Linaclotide (Correct answer)
- Eluxadoline
Correct answer: Linaclotide
Linaclotide (Linzess) is FDA-approved for IBS-C and chronic idiopathic constipation. It is a guanylate cyclase-C agonist that increases intestinal fluid secretion and accelerates transit. Alosetron is approved for severe IBS-D (diarrhea-predominant) in women only. Rifaximin is approved for IBS-D. Eluxadoline is approved for IBS-D.
Question 6: A patient with ulcerative colitis limited to the rectum (proctitis) presents with mild-to-moderate active disease. Which formulation of mesalamine is MOST appropriate as first-line therapy for this presentation?
- Oral mesalamine (delayed-release tablet) alone
- Mesalamine rectal suppository alone (Correct answer)
- Combination of oral and rectal mesalamine
- Systemic corticosteroids (prednisone) as initial therapy
Correct answer: Mesalamine rectal suppository alone
For mild-to-moderate ulcerative proctitis, topical (rectal) mesalamine formulations (suppositories or enemas) are the preferred first-line therapy. Suppositories deliver drug directly to the affected mucosa in proctitis. ACG guidelines indicate topical 5-ASA is superior to oral 5-ASA for proctitis and is more effective than topical corticosteroids. Systemic corticosteroids are reserved for more severe or refractory disease. Combination therapy (oral + rectal) is an option for more extensive disease or if topical alone is insufficient.
BCACP Gastrointestinal Disorders Management
A patient is diagnosed with Helicobacter pylori-associated peptic ulcer disease.
He has no penicillin allergy and has not previously received clarithromycin.
Which regimen is considered first-line eradication therapy in areas with known clarithromycin resistance rates below 15%?